The use of magrolimab plus rituximab in R/R indolent NHL

Mark Roschewski, MD, NCI Center for Cancer Research, Bethesda, MD, discusses the use of magrolimab combined with rituximab in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (NHL). The findings of this study indicate that over 40% of patients achieve complete responses (CRs), with some being durable responses, highlighting the potential of this pathway in developing new treatments for B-cell lymphomas. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.